PatternsRadar
Sign in

NATCOPHARMNatco Pharma Limited

NSE
Full chart
823.65INR+2.15 (+0.26%)Close · 6 Oct 2026
14 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹16,157 CrMarket cap
14.1P/E (TTM)
61.9%Delivery

Filings & corporate actions

85 results filed
CSV
Next results · Q2 FY27
Expected 10 Nov 2026 – 14 Nov 2026
Estimate: filed 41–45 days after quarter end, last 5 times
Dividend
₹1.50 per share · last 20 Aug 2026
2026
  • 1 OctrightsRights 2:21 @ Premium Rs 748/--0.7%
  • 20 AugdividendDividend · ₹1.50 per share-1.1%
  • 14 AugresultsResults · Q1 FY27 · consolidated and standalone-1.5%NSE
  • 9 JulshareholdingShareholding · 30 Jun 2026-0.5%NSE
  • 29 MayresultsResults · Q4 FY26 · consolidated and standalone-8.1%NSE
  • 9 AprshareholdingShareholding · 31 Mar 2026+1.0%NSE
  • 18 FebdividendDividend · ₹1.50 per share+0.7%
  • 12 FebresultsResults · Q3 FY26 · consolidated and standalone-1.9%NSE
  • 19 JanshareholdingShareholding · 31 Dec 2025-1.6%NSE

Reaction to results · all yearsrose on day 0 in 27 of 78 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2714 Aug 2026-1.5%-2.1%-9.3%1.9×
Q4 FY2629 May 2026-8.1%-14.5%-8.3%3.9×
Q3 FY2612 Feb 2026-1.9%+6.2%+12.7%0.9×
Q2 FY2614 Nov 2025+1.0%+3.5%+11.4%1.2×
Q1 FY2612 Aug 2025+1.8%-0.8%-2.9%0.5×
Q4 FY2528 May 2025+3.6%-0.1%+1.0%6.8×
Q3 FY2512 Feb 2025-20.0%-34.9%-34.3%18.2×
Q2 FY2512 Nov 2024-1.7%-2.4%+3.7%4.4×
Q1 FY2512 Aug 2024-1.3%-1.5%+6.5%1.5×
Q4 FY2427 May 2024+0.3%-5.7%+14.4%9.9×
Q3 FY2414 Feb 2024+0.3%+14.0%+10.5%2.6×
Q2 FY2414 Nov 2023-4.5%+0.7%-3.7%4.2×
Q1 FY249 Aug 2023-2.0%-3.2%-1.3%1.5×
Q4 FY2329 May 2023-2.1%-2.0%+8.3%1.8×
Q3 FY239 Feb 2023-0.9%+1.0%+2.8%0.9×
Q2 FY2310 Nov 2022-0.7%-2.4%-3.4%1.8×
Q1 FY239 Aug 2022-10.3%-13.0%-19.8%8.5×
Q4 FY2231 May 2022+3.7%+3.7%-3.9%14.3×
Q3 FY2214 Feb 2022-2.4%-8.4%-8.5%3.6×
Q2 FY2211 Nov 2021+0.6%-1.9%+7.2%1.5×
Q1 FY2212 Aug 2021-5.1%-13.4%-6.3%0.9×
Q4 FY2117 Jun 2021+1.2%+1.3%+2.4%1.0×
Q3 FY2111 Feb 2021-3.6%-8.1%-6.7%3.6×
Q2 FY2112 Nov 2020-0.6%+0.5%+4.5%2.6×
Q1 FY2112 Aug 2020-4.2%-1.2%-8.2%0.8×
Q4 FY2017 Jun 2020+1.0%+3.7%+11.8%0.7×
Q3 FY2012 Feb 2020-4.9%-6.5%-20.9%3.7×
Q2 FY2012 Nov 2019-3.2%-4.1%+0.6%2.0×
Q1 FY209 Aug 2019-0.6%-2.1%+3.1%1.4×
Q4 FY1927 May 2019+0.9%+3.3%+2.2%8.6×
Q3 FY1919 Feb 2019+1.1%+0.9%+2.8%1.0×
Q2 FY1919 Nov 2018-1.7%-4.1%-4.9%1.1×
Q1 FY1924 Aug 2018+1.0%+3.3%-0.7%0.8×
Q4 FY181 Jun 2018-1.0%-2.6%-0.3%1.6×
Q3 FY189 Feb 2018-1.9%-3.1%-10.2%0.9×
Q2 FY183 Nov 2017+0.2%-2.4%-1.0%1.0×
Q1 FY1821 Aug 2017-4.4%-4.4%+5.7%0.4×
Q4 FY1715 Jun 2017+2.1%+0.4%+2.0%2.0×
Q3 FY1722 Feb 2017+4.5%-0.4%-0.5%2.8×
Q2 FY1715 Nov 2016-2.6%-9.9%-9.9%2.4×
Q1 FY171 Oct 2016+0.4%0.0%-1.7%1.7×
Q4 FY1627 May 2016+0.2%+11.7%+23.8%4.9×
Q3 FY1618 Feb 20160.0%-3.8%+2.3%0.5×
Q2 FY1613 Nov 2015-0.1%+5.4%+11.3%0.7×
Q1 FY1612 Aug 2015-5.6%-3.3%-9.6%1.6×
Q4 FY1515 Jun 2015-0.8%+7.3%+12.6%0.4×
Q3 FY1517 Feb 2015-0.1%-3.2%+54.3%0.2×
Q2 FY1521 Nov 2014-1.7%-1.3%+0.9%0.8×
Q1 FY1520 Aug 2014-1.1%+7.3%+33.2%0.8×
Q4 FY143 Jun 2014-1.1%+7.2%+33.2%0.3×
Q3 FY1420 Feb 2014-1.1%+7.8%+4.4%0.5×
Q2 FY1422 Nov 2013+1.5%+1.3%+6.5%0.7×
Q1 FY1421 Aug 2013+1.2%-0.2%+5.2%0.6×
Q4 FY138 Jun 20130.0%+3.7%+6.9%0.2×
Q3 FY1320 Feb 2013-0.5%-4.0%-1.9%0.1×
Q2 FY138 Nov 2012+2.5%+5.4%+22.2%8.2×
Q1 FY1313 Aug 2012+1.7%-3.2%+4.9%1.1×
Q4 FY1229 May 2012-1.8%-9.7%-15.3%1.1×
Q3 FY129 Feb 2012+1.6%+2.5%+14.6%3.9×
Q2 FY129 Nov 2011-3.0%-11.7%+4.2%0.3×
Q1 FY1217 Aug 2011-0.9%-0.2%-6.2%0.5×
Q4 FY113 Jun 2011-1.0%-1.0%-5.2%0.5×
Q3 FY1114 Feb 2011+0.3%-6.5%-7.7%1.3×
Q2 FY1115 Nov 2010-0.5%+0.6%-1.4%0.6×
Q1 FY1131 Jul 2010-0.6%+2.8%+35.2%0.4×
Q4 FY1025 Jun 2010+3.0%+9.3%+4.7%2.9×
Q3 FY1027 Jan 2010+0.2%+1.8%+7.4%0.5×
Q2 FY1029 Oct 2009-2.8%-4.6%-4.6%0.7×
Q1 FY1030 Jul 2009-4.0%-4.6%+31.9%0.8×
Q4 FY0930 Jun 2009-2.7%-4.3%-1.8%0.6×
Q3 FY0927 Jan 2009+6.5%+4.3%+3.8%2.6×
Q2 FY0931 Oct 2008+9.2%+18.4%+20.7%1.1×
Q1 FY0931 Jul 2008-0.7%+10.9%+5.5%0.7×
Q4 FY0830 Jun 2008-1.3%-7.4%-2.0%1.3×
Q3 FY0825 Jan 2008-3.0%+1.7%-8.7%0.2×
Q2 FY0826 Oct 2007-0.2%+0.6%+3.1%1.0×
Q1 FY0826 Jul 2007-0.8%-6.8%-17.0%1.5×
Q4 FY0729 Jun 2007-6.4%-11.5%-19.1%1.6×
Average-1.0%-1.2%+2.6%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY-44.7%
Profit YoY-57.0%
Interest cost YoY—
Revenue QoQ-0.5%
Profit QoQ-23.2%
CAGR2Y3Y4Y5Y6Y7Y
Revenue——————
Profit——————

Key data

CSV
Open824.70
Day range815.35 – 827.00
52-week range789.00 – 1,226.80
From 52w high-32.9%
RSI (14)42.4
ATR (14)21.63
Volume2.25L
Avg volume (20D)4.79L
Rel volume0.47×
Volatility (1Y)36.7%
Turnover₹18.5Cr
SMA 50 / 200865.61 / 939.58

Delivery percentage

Latest · 6 Oct 202661.9%
20-day avg52.4%
1-year avg41.1%
Percentile (own history)80th
Range7.6–96.2%
Sessions1,731

Over the last 20 sessions NATCOPHARM settled 52.4% of its traded quantity, which is above average for an NSE equity. Its one-year average is 41.1%, so recent sessions are running 11.3 points higher than usual. The latest session ranks higher than 80% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+0.26%-0.59%-1.75%-16.31%-19.84%+0.35%

Valuation

CSV
Market cap₹16,157 Cr
P/E (TTM)14.1
EPS (TTM)58.35
Shares outstanding17.90Cr
Listed27 Dec 1995

Ownership

CSV
Promoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)1,363.0647.3739.1735.2
YoY chg——-39.5%-44.7%
Net profit (₹ Cr)517.9151.3269.0206.5
YoY chg——-33.7%-57.0%
Net margin38.0%23.4%36.4%28.1%
EPS28.948.4614.9611.53

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 49.42% · public 50.58%
30 Sept 2021: promoter 48.87%31 Dec 2021: promoter 48.86%31 Mar 2022: promoter 48.81%30 Jun 2022: promoter 48.80%30 Sept 2022: promoter 48.80%31 Dec 2022: promoter 48.82%31 Mar 2023: promoter 48.84%30 Jun 2023: promoter 49.76%30 Sept 2023: promoter 49.71%31 Dec 2023: promoter 49.71%31 Mar 2024: promoter 49.71%30 Jun 2024: promoter 49.71%30 Sept 2024: promoter 49.62%31 Dec 2024: promoter 49.62%31 Mar 2025: promoter 49.56%30 Jun 2025: promoter 49.56%30 Sept 2025: promoter 49.48%31 Dec 2025: promoter 49.48%31 Mar 2026: promoter 49.42%30 Jun 2026: promoter 49.42%
2021-092026-06
  • Promoter
  • Public and others
Promoter
49.42%
Public
50.58%
Promoter change
0.00 pp
Filed
9 Jul 2026
FII
16.99%
DII
5.62%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations1,031.4758.61,068.31,362.61,371.1474.81,221.01,328.91,363.0647.3739.1735.2
Other income29.437.042.048.163.8176.366.361.7100.058.177.859.2
Total income1,060.8795.61,110.31,410.71,434.9651.11,287.31,390.61,463.0705.4816.9794.4
Total expenses621.2539.3632.7607.1616.7487.4781.4818.7849.3544.3672.8608.8
└ Finance costs4.24.66.25.24.14.410.23.213.19.510.913.0
└ Depreciation43.644.255.544.145.847.098.357.652.446.250.447.1
Profit before tax439.6256.3477.6803.6818.2163.7505.9571.9613.7161.1144.1185.6
Tax expense70.643.691.3135.1141.731.399.991.695.820.7(89.2)63.4
Net profit369.0212.7386.3668.5676.5132.4406.0480.3517.9151.3269.0206.5
EPS20.6011.8821.5637.3237.817.4322.7026.8428.948.4614.9611.53
Net margin35.78%28.04%36.16%49.06%49.34%27.89%33.25%36.14%38.00%23.37%36.40%28.09%
PBT margin42.62%33.79%44.71%58.98%59.67%34.48%41.43%43.04%45.03%24.89%19.50%25.24%
Tax rate16.06%17.01%19.12%16.81%17.32%19.12%19.75%16.02%15.61%12.85%-61.90%34.16%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 14 Aug 2026.

NATCOPHARM at a glance

  • NATCOPHARM closed at ₹823.65 on 6 Oct 2026, +0.26% on the day, +0.4% over one year, 32.9% below its 52-week high of ₹1,226.8.
  • Delivery was 61.9% of traded quantity on 6 Oct 2026, the 80th percentile of its own 1,731 sessions with a reading (20-session average 52.4%, 1-year average 41.1%).
  • Market capitalisation is ₹16,157 crore at a trailing P/E of 14.1 (trailing EPS ₹58.35).
  • Q1 FY27 results (consolidated, filed 14 Aug 2026): revenue ₹735 crore (-44.7% year on year), net profit ₹207 crore (-57.0%); the price moved -1.5% on the first session after.
  • Promoters held 49.42% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 10 Nov 2026 and 14 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE987B01026
SeriesEQ
Listed27 Dec 1995
History from27 Dec 1995
Sessions7,602
Turnover rank#544

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE